299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details
臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-003277-55-AT (EUCTR) | 01/09/2021 | 27/07/2021 | COVID-19 Antibody Responses in Cystic Fibrosis: CAR-CF | COVID-19 Antibody Responses in Cystic Fibrosis: CAR-CF - CAR-CF | COVID-19 vaccine Antibody response from natural infection or after vaccination in patients with Cystic Fibrosis (CF) MedDRA version: 20.0;Level: LLT;Classification code 10021433;Term: Immunization;System Organ Class: 100000004865 MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Not possible to specify | Trade Name: Comirnaty concentrate for dispersion for injection Product Name: Comirnaty INN or Proposed INN: Tozinameran Other descriptive name: COVID-19 mRNA vaccine (nucleoside-modified) Trade Name: Vaxzevria suspension for injection COVID-19 Vaccine (ChAdOx1-S Product Name: Vaxzevria INN or Proposed INN: COVID-19 Vaccine (ChAdOx1-S [recombinant]) Other descriptive name: COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19) Trade Name: COVID-19 Vaccine Moderna dispersion for injection Product Name: COVID-19 Vaccine Moderna INN or Proposed INN: Elasomeran Other descriptive name: COVID-19 mRNA vaccine Moderna (CX-024414) Trade Name: COVID-19 Vaccine Janssen suspension for injection Product Name: COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant]) INN or Proposed INN: COVID-19 vaccine (Ad26.COV2-S [recombinant]) Other descriptive name: Ad26.COV2-S.02 | Medical University of Innsbruck, University Clinic for Pediatrics III | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 5000 | Phase 4 | United States;European Union;Canada;Ireland;Austria;United Kingdom |